Analyst Conference Summaries |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Syros Pharmaceuticals
|
2024 | |||
Syros Pharmaceuticals Q4 2023 |
Syros Pharmaceuticals Q1 2024 |
Syros Pharmaceuticals Q2 2024 |
|
March 27, 2024 | May 14, 2024 | July 31, 2024 | |
2023 | |||
Syros Pharmaceuticals Q4 2022 |
Syros Pharmaceuticals Q1 2023 |
Syros Pharmaceuticals Q2 2023 |
Syros Pharmaceuticals Q3 2023 |
March 2, 2023 | May 10, 2023 | Aug. 8, 2023 | Nov. 14, 2023 |
2022 | |||
Syros Pharmaceuticals Q4 2021 |
Syros Pharmaceuticals Q1 2022 |
Syros Pharmaceuticals Q2 2022 |
Syros Pharmaceuticals Q3 2022 |
March 15, 2022 | May 16, 2022 | Aug. 9, 2022 | Nov. 14, 2022 |
2021 | |||
Syros Pharmaceuticals Q4 2020 |
Syros Pharmaceuticals Q1 2021 |
Syros Pharmaceuticals Q2 2021 |
Syros Pharmaceuticals Q3 2021 |
March 4, 2021 | May 6, 2021 | Aug. 5, 2021 | Nov. 5, 2021 |
2020 | |||
Syros Pharmaceuticals Q4 2019 |
Syros Pharmaceuticals Q1 2020 |
Syros Pharmaceuticals Q2 2020 |
Syros Pharmaceuticals Q3 2020 |
March 5, 2020 | May 7, 2020 | Aug. 6, 2020 | Nov. 5, 2020 |
Syros Pharmaceuticals Update: Still a Buy [January 23, 2020 at Seeking Alpha]
Syros Pharmaceuticals Platform Undervalued [April 10, 2019 at Seeking Alpha]
Syros Pharmaceuticals (SYRS) is a clinical-stage biotechnology company with a platform based on gene regulation.
More Analyst Conference Pages:
AGEN |
AGIO |
ALLO |
ALNY |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BLRX |
BLUE |
BMY |
CLDX |
CDTX |
FATE |
GILD |
GLYC |
INCY |
INO |
IONS |
MCHP |
MRNA |
PLX |
REGN |
RNA |
SAGE |
SANA |
TSVT |
VRTX |
VSTM |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers